On September 27, 2020, Zhu Shanhua, Vice Chairman of Lishui Municipal Committee of the Chinese People's Political Consultative Conference (CPPCC), Chen Haihua, Chairman of Liandu District Overseas Chinese Federation, Chen Jianchun, Vice President of China Overseas Chinese Chamber of Commerce, and other leaders visited Zhejiang Benefit Pharmaceutical for research and guidance. Wu Liwei, Executive Director of the company, and senior management warmly received them.

Zhang Liyun, Administrative Director, introduced various production links and R&D situations through a remote real-time video system, and gave a brief report on the basic overview of the company's four sectors, corporate culture, and Benefit's development strategic layout plan for the next five years.

At the forum, Executive Director Wu Liwei introduced the current production status of Benefit's traditional Chinese medicine formula granules, product quality control, and the actual efficacy of traditional Chinese medicine formula granules in the prevention of COVID-19 during the epidemic. During the epidemic, to ensure that overseas Chinese could fight the epidemic and take traditional Chinese medicine as soon as possible, all employees of the company worked overtime to carry out production and quickly responded to the government's procurement needs for aiding overseas. At the same time, Executive Director Wu Liwei also gave a detailed introduction to the future development positioning of traditional Chinese medicine formula granules.

Subsequently, the participants from both sides conducted comprehensive and in-depth exchanges and discussions on the production technology of traditional Chinese medicine formula granules, product convenience, quality assurance, effectiveness, and the efficacy of single-flavor traditional Chinese medicine formula granules in clinical treatment.

Chen Jianchun, Vice President of China Overseas Chinese Chamber of Commerce, stated that as a modern traditional Chinese medicine production enterprise, Benefit undertakes the mission of promoting, inheriting, researching, and developing traditional Chinese medicine culture and serving the cause of human health. It is hoped that Benefit will strengthen traditional Chinese medicine scientific research in the future to promote the development of national quintessence culture.

Finally, Vice Chairman Zhu Shanhua said that traditional medicine is an important carrier of excellent traditional culture and plays an important role in promoting cultural exchanges and mutual learning and safeguarding people's health. Traditional Chinese medicine is an outstanding representative of it, widely recognized by people in many countries for its unique advantages in disease prevention, treatment, and rehabilitation. During the prevention and treatment of COVID-19, traditional Chinese medicine was widely used and its efficacy was affirmed. In particular, traditional Chinese medicine formula granules, with their convenience in carrying and storage, were widely used in epidemic prevention and treatment at home and abroad. Traditional Chinese medicine is a treasure of the Chinese nation. As the only enterprise in Lishui engaged in the production of traditional Chinese medicine formula granules, it should take advantage of Lishui's green ecological environment, strengthen research on proven folk prescriptions with definite curative effects, and by leveraging the advantages of traditional Chinese medicine formula granules such as precise ingredient content and definite efficacy, earnestly protect, explore, develop, and inherit this precious wealth left by our ancestors.